You are here

Article Text

Article menu
Download PDFPDF
Novel treatment (new drug/intervention; established drug/procedure in new situation)
Case report
Pegloticase hypersensitivity desensitisation: an outpatient, 3-bag, 12-step protocol
  1. John K Botson
  1. Orthopedic Physicians Alaska, Anchorage, Alaska, USA
  1. Correspondence to Dr John K Botson; jbotson{at}opaak.com

Abstract

Pegloticase is a highly effective treatment for refractory gouty arthropathy. Unfortunately, the medication is also highly immunogenic, leading to infusion reactions, loss of drug efficacy and anaphylaxis. Desensitisation, a procedure to tolerise a patient to a medication previously causing a hypersensitivity reaction, has been used successfully in oncology for chemotherapy treatment. The same principle can be applied to other specialties. Presented is a 48-year-old man who experienced multiple, severe infusion reactions to pegloticase administered for gouty arthropathy. A rapid desensitisation was performed using an outpatient, 3-bag, 12-step protocol, which allowed multiple additional pegloticase infusions to be performed without incident. This is the first reported case of a patient successfully desensitised after an infusion reaction to pegloticase. Though additional patients are needed to confirm these results, this represents a significant opportunity to recapture and continue pegloticase therapy in patients treated for refractory gouty arthropathy.

  • rheumatology
  • immunology

https://doi.org/10.1136/bcr-2020-234721

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors JKB was solely responsible for all aspects of the work including drafting, reviewing and approving the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests JKB reports personal fees from Horizon Therapeutics, outside the submitted work.

    • Patient consent for publication Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.